The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Iron management in chronic kidney disease: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference
Open accessAbstract
Before the introduction of erythropoiesis-stimulating agents (ESAs) in 1989, repeated transfusions given to patients with end-stage renal disease caused iron overload, and the need for supplemental iron was rare. However, with the widespread introduction of ESAs, it was recognized that supplemental iron was necessary to optimize hemoglobin response and allow reduction of the ESA dose for economic reasons and recent concerns about ESA safety. Iron supplementation was also found to be more efficacious via intravenous compared to oral administration, and the use of intravenous iron has escalated in recent years. The safety of various iron compounds has been of theoretical concern due to their potential to induce iron overload, oxidative stress, hypersensitivity reactions, and a permissive environment for infectious processes. Therefore, an expert group was convened to assess the benefits and risks of parenteral iron, and to provide strategies for its optimal use while mitigating the risk for acute reactions and other adverse effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Self-citationThe Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
The SPRINT Research Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1511939 · Cited by 6,325
Flynn, J. T., Kaelber, D. C., Baker-Smith, C. M., Blowey, D., Carroll, A. E., Daniels, S. R., de Ferranti, S. D., Dionne, J. M., Falkner, B., Flinn, S. K., et al. (2017) · Pediatrics · doi:10.1542/peds.2017-1904 · Cited by 3,651
Effects of intensive blood-pressure control in type 2 diabetes mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001286 · Cited by 3,598
Zelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Furtado, R. H. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32590-x · Cited by 2,845
Spironolactone for heart failure with preserved ejection fraction
Pitt, B., Pfeffer, M. A., Assmann, S. F., Boineau, R., Anand, I. S., Claggett, B., Clausell, N., Desai, A. S., Diaz, R., Fleg, J. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1313731 · Cited by 2,809
Cited by
Cheung, A. K., Chang, T. I., Cushman, W. C., Furth, S. L., Hou, F. F., Ix, J. H., Knoll, G. A., Muntner, P., Pecoits-Filho, R., Sarnak, M. J., et al. (2021) · Kidney International · doi:10.1016/j.kint.2020.11.003 · Cited by 1,452
Self-citationCamaschella, C. (2019) · Blood · doi:10.1182/blood-2018-05-815944 · Cited by 702
Single-dose intravenous iron for iron deficiency: a new paradigm
Auerbach, M., & Deloughery, T. (2016) · Hematology · doi:10.1182/asheducation-2016.1.57 · Cited by 148
Self-citationWong, M. M. Y., Tu, C., Li, Y., Perlman, R. L., Pecoits-Filho, R., Lopes, A. A., Narita, I., Reichel, H., Port, F. K., Sukul, N., et al. (2020) · Clinical Kidney Journal · doi:10.1093/ckj/sfz091 · Cited by 140
Self-citationSucrosomial® Iron: A New Generation Iron for Improving Oral Supplementation
Gómez-Ramírez, S., Brilli, E., Tarantino, G., & Muñoz, M. (2018) · Pharmaceuticals · doi:10.3390/ph11040097 · Cited by 132
Role of divalent metals in infectious disease susceptibility and outcome
Weiss, G., & Carver, P. L. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2017.01.018 · Cited by 123
Iatrogenic Iron Overload in Dialysis Patients at the Beginning of the 21st Century
Rostoker, G., Vaziri, N. D., & Fishbane, S. (2016) · Drugs · doi:10.1007/s40265-016-0569-0 · Cited by 71
Self-citationDiagnosis and management of malnutrition in patients with heart failure
Esteban-Fernández, A., Villar-Taibo, R., Alejo, M., Arroyo, D., Bonilla Palomas, J. L., Cachero, M., Joaquin, C., Méndez Bailón, M., Pérez-Rivera, J. Á., Romero-Vigara, J. C., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12093320 · Cited by 61
Safety of intravenous iron use in chronic kidney disease
Kalra, P. A., & Bhandari, S. (2016) · Current Opinion in Nephrology and Hypertension · doi:10.1097/mnh.0000000000000263 · Cited by 50
Self-citation
Metadata
- Authors
- Macdougall, I. C., Bircher, A. J., Eckardt, K.-U., Obrador, G. T., Pollock, C. A., Stenvinkel, P., Swinkels, D. W., Wanner, C., Weiss, G., Chertow, G. M., Adamson, J. W., Akizawa, T., Anker, S. D., Auerbach, M., Bárány, P., Besarab, A., Bhandari, S., Cabantchik, I., Collins, A. J., Coyne, D. W., de Francisco, Á. L. M., Fishbane, S., Gaillard, C. A. J. M., Ganz, T., Goldsmith, D. J., Hershko, C., Jankowska, E. A., Johansen, K. L., Kalantar-Zadeh, K., Kalra, P. A., Kasiske, B. L., Locatelli, F., Małyszko, J., Mayer, G., McMahon, L. P., Mikhail, A., Nemeth, E., Pai, A. B., Parfrey, P. S., Pecoits-Filho, R., Roger, S. D., Rostoker, G., Rottembourg, J., Singh, A. K., Slotki, I., Spinowitz, B. S., Tarng, D.-C., Tentori, F., Toblli, J. E., Tsukamoto, Y., Vaziri, N. D., Winkelmayer, W. C., Wheeler, D. C., & Zakharova, E.
- Venue
- Kidney International
- Publisher
- Elsevier BV
- Published
- 2016-01
- Volume
- 89
- Issue
- 1
- Pages
- 28-39
- ISSN
- 0085-2538 (ISSN-L)
- OpenAlex
- W2222807855
- Cited by
- 482
- References
- 52
- FWCI
- 35.02
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.